Roche Holding AG and Actavis Group HF, an Iceland-based generics company, have signed agreements for the sale of three of Roche's pharmaceutical products to Actavis for an undisclosed sum.
The Basel-based drug maker said that product rights -- with some territorial exceptions -- for cardiovascular drugs Bezalip and Rapilysin and dermatology product Neotigason are being transferred to Actavis.
More
No comments:
Post a Comment